Risdiplam
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Muscular Atrophy, Spinal
Conditions
Muscular Atrophy, Spinal
Trial Timeline
May 30, 2024 → Mar 31, 2029
NCT ID
NCT05861986About Risdiplam
Risdiplam is a approved stage product being developed by Roche for Muscular Atrophy, Spinal. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05861986. Target conditions include Muscular Atrophy, Spinal.
What happened to similar drugs?
14 of 20 similar drugs in Muscular Atrophy, Spinal were approved
Approved (14) Terminated (2) Active (5)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05861999 | Approved | Recruiting |
| NCT05861986 | Approved | Recruiting |
| NCT05808764 | Phase 2 | Recruiting |
| NCT03779334 | Phase 2 | Active |
| NCT03920865 | Phase 1 | Completed |
| NCT03032172 | Phase 2 | Completed |
| NCT02913482 | Phase 2 | Completed |
Competing Products
20 competing products in Muscular Atrophy, Spinal